Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.
Maturitas. 2011 Oct;70(2):194-6. doi: 10.1016/j.maturitas.2011.07.018. Epub 2011 Aug 9.
Within the past two years, three agents have garnered approval from the US FDA for the specific treatment of metastatic castration resistant prostate cancer (mCRPC) - (1) abiraterone, (2) cabazitaxel and (3) sipuleucel-T. In separate phase III studies, each agent led to an improvement in overall survival (OS) of 2-4 months over a suitable comparator. With these costly therapies all having potential application in the patient with mCRPC, multiple entities (industry, government, and the general public) must strategize to determine how the cost burden of these agents can be balanced with the potential gains for the individual patient. Herein, we provide a framework with which to approach this dilemma.
在过去的两年中，有三种药物获得了美国 FDA 的批准，用于治疗转移性去势抵抗性前列腺癌（mCRPC）：（1）阿比特龙，（2）卡巴他赛，和（3）sipuleucel-T。在单独的 III 期研究中，每种药物与合适的对照药物相比，均使总生存期（OS）延长了 2-4 个月。由于这些昂贵的治疗方法都有可能应用于 mCRPC 患者，因此多个实体（行业、政府和公众）必须制定策略，以确定如何平衡这些药物的成本负担与个体患者的潜在获益。在此，我们提供了一种方法来解决这个难题。
